Colon | Esophagus | Liver | Pancreas, Phase II
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers
Volunteers
Health Professionals
What is the purpose of this trial?
Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells.
The main goal of this study is to learn if the cancer responds to treatment (gets smaller or goes away).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Clarice Grens
- Elan Gorshein, DO, JD, MPH
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Kristen Hoxie
- Michael Cecchini, MD
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Sara Anastasio, RN
- Sarah Carlson
- Su Hsien Lim, MD
- Teresa White
- Thejal Srikumar, MD, MPH
- Vanna Dest
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Last Updated07/08/2025
- Study HIC#2000039419